Outpatient cognitive behavioural therapy programme for alcohol dependence: impact of naltrexone use on outcome

References

• Holder H D, Blose J O. The reduction of health care costs associated with alcoholism treatment: a 14-year longitudinal study. Journal of Studies on Alcohol 1992; 53: 293–302
   PubMed Web of Science ®Google Scholar
• Matching alcoholism treatments to client heterogeneity. Project MATCH posttreatment outcomes. Journal of Studies on Alcohol 1997; 58: 7–29
   PubMed Web of Science ®Google Scholar
• Finney J, Monahan S C. The cost effectiveness of treatment for alcoholism: a second approximation. Journal of Studies on Alcohol 1996; 57: 229–243
   PubMed Web of Science ®Google Scholar
• Holder H, Longabaugh R, Miller W R, Rubonis A V. The cost effectiveness of treatment for alcoholism: a first Approximation. Journal of Studies on Alcohol 1991; 52: 517–540
   PubMed Web of Science ®Google Scholar
• Bandura A. Self-efficacy: toward a unifying theory of behavioural change. Psychological Review 1977; 84: 191–215
   PubMed Web of Science ®Google Scholar
• Marlatt G A, Gordon J R. Relapse prevention. Guilford, New York 1985
   Google Scholar
• Kadden R M. Is Marlatt's relapse taxonomy reliable or valid?. Addiction. 1996; 91 (Suppl.): S139–S145
   Google Scholar
• Hughes J C, Cook C C. The efficacy of disulfiram: a review of the outcome studies. Addiction 1997; 92: 381–395
   PubMed Web of Science ®Google Scholar
• Cornelius J R, Salloum I M, Ehler J G, et al. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Archives of General Psychiatry 1997; 54: 700–705
   PubMed Web of Science ®Google Scholar
• Kranzler H R, Burleson J A, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. American Journal of Psychiatry 1995; 152: 391–397
   PubMed Web of Science ®Google Scholar
• Kabel D I, Petty F. A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcoholism: Clinical and Experimental Research 1996; 20: 780–784
   PubMed Web of Science ®Google Scholar
• Malec E, Malec T, Gagne M A, Dongier M. Buspirone in the treatment of alcohol dependence: a placebo-controlled trial. Alcoholism: Clinical and Experimental Research 1996; 20: 307–312
   PubMed Web of Science ®Google Scholar
• Mueller T I, Stout R L, Rudden S, et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcoholism: Clinical and Experimental Research 1997; 21: 86–92
   PubMed Web of Science ®Google Scholar
• Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Archives of General Psychiatry 1996; 53: 673–680
   PubMed Web of Science ®Google Scholar
• Pelc I, Verbanck P, LeBon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: a 90-day placebo-controlled dose-finding study. British Journal of Psychiatry 1997; 171: 73–77
   PubMed Web of Science ®Google Scholar
• Volpicelli J R, Alterman A I, Hayashida M, O'Brien C P. Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry 1992; 49: 876–880
   PubMed Web of Science ®Google Scholar
• O'Malley S S, Jaffe A J, Chang G, Schottenfeld R S, Leyer R E, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Archives of General Psychiatry 1992; 49: 881–887
   PubMed Web of Science ®Google Scholar
• O'Malley S S, Jaffe A J, Chang G, et al. Six-month follow-up of Naltrexone and psychotherapy for alcohol dependence. Archives of General Psychiatry 1996; 53: 217–224
   PubMed Web of Science ®Google Scholar
• Anton R F, Moak D H, Waid L R, Latham P K, Malcolm R J, Dias J K. Naltrexone and cognitive behavioural therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. American Journal of Psychiatry 1999; 156: 1758–64
   PubMed Web of Science ®Google Scholar
• Ulm R R, Volpicelli J R, Volpicelli L A. Opiates and alcohol self-administration in animals. Journal of Clinical Psychiatry 1995; 56(Suppl. 7)5–14
   PubMed Web of Science ®Google Scholar
• Carter S K. Clinical considerations in the design of clinical trials. Cancer Treatment Reports 1980; 64: 367–371
   PubMedGoogle Scholar
• Fong I W, Ho J, Toy C, Lo B, Fong M W. Value of long-term administration of acyclovir and similar agents for protecting against AIDS-related lymphoma: case-control and historical cohort studies. Clinical Infectious Diseases 2000; 30: 757–761
   PubMed Web of Science ®Google Scholar
• Ellison G W, Mickey M R, Myers L W. Alternatives to randomized clinical trials. Neurology 1988; 38(Suppl. 2)73–75
   PubMed Web of Science ®Google Scholar
• Bhansali M S, Patil P K, Badwe R A, Havalda R, Desai P B. Historical control bias: adjuvant chemotherapy in esophageal cancer. Diseases of the Esophagus 1997; 10: 51–54
   PubMedGoogle Scholar
• Foster J H, Marshall E J, Hooper R, Peters T J. Quality of life measures in alcohol dependent subjects and changes with abstinence and continued heavy drinking. Addiction Biology 1998; 3: 321–332
   PubMed Web of Science ®Google Scholar
• Hunt W A, Barnett W, Branch L G. Relapse rates in addiction programs. Journal of Clinical Psychology 1971; 27: 455–456
   PubMed Web of Science ®Google Scholar
• Project MATCH Research Group. Matching alcoholism treatments to client heterogeneity. Treatment main effects on drinking during treatment. Journal of Studies on Alcohol 1998; 59: 631–639
   PubMed Web of Science ®Google Scholar
• Schuckit M A, Tipp J E, Smith T L, Bucholz K K. Periods of abstinence following the onset of alcohol dependence in 1,853 men and women. Journal of Studies on Alcohol 1997; 58: 581–589
   PubMed Web of Science ®Google Scholar